OncoLab Co. Ltd.

OncolaB is an innovative bio-venture company that has developed the next-generation immune-oncology treatment platform ANGel, which possesses excellent drug delivery, efficacy, and sustainability. Founded in May 2024 by CEO Jongseong Kim, who has over 20 years of experience in nanogel research, the company received an investment of $500,000. Additionally, OncolaB was selected as a Deep Tech TIPS company by the Chungbuk Creative Economy Innovation Center, and secured further support of $1,500,000. Our company is developing treatment technologies for difficult-to-treat cancers, including triple-negative breast cancer and various solid tumors, with the following vision.